Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-Inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax ACWY.

Trial Profile

Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-Inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax ACWY.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 02 Nov 2016 Last checked against ClinicalTrials.gov record.
    • 30 Apr 2008 Status changed from in progress to completed.
    • 25 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top